An Illinois-based biotech company is already off to the races on Tuesday after it was announced that the company has entered into an agreement with Gilead Sciences, Inc. (Nasdaq:GILD) to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate, according to the release. 

Adding to the continued biotech rally, shares of Compugen Ltd. (Nasdaq:CGEN) opened up at $2.03/share (+178.08%) on Tuesday. This was a major technical breakout for this small cap!

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.